La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

NanoViricides Croissance future

Future contrôle des critères 0/6

NanoViricides devrait augmenter ses bénéfices et ses revenus de 10.3% et de 63% par an respectivement, tandis que le BPA devrait croître de croître de 17.8% par an.

Informations clés

14.2%

Taux de croissance des bénéfices

21.7%

Taux de croissance du BPA

Biotechs croissance des bénéfices	27.9%
Taux de croissance des recettes	61.0%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	10 Jul 2024

Mises à jour récentes de la croissance future

Recent updates

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

Feb 18

Prévisions de croissance des bénéfices et des revenus

NYSEAM:NNVC - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2027	7	-6	-4	-4	1
6/30/2026	3	-8	-5	-5	1
6/30/2025	N/A	-15	-9	-8	2
6/30/2024	N/A	-8	-6	-6	N/A
3/31/2024	N/A	-10	-6	-6	N/A
12/31/2023	N/A	-9	-6	-6	N/A
9/30/2023	N/A	-9	-6	-6	N/A
6/30/2023	N/A	-9	-6	-6	N/A
3/31/2023	N/A	-7	-6	-6	N/A
12/31/2022	N/A	-7	-6	-5	N/A
9/30/2022	N/A	-7	-7	-6	N/A
6/30/2022	N/A	-8	-6	-6	N/A
3/31/2022	N/A	-8	-7	-7	N/A
12/31/2021	N/A	-9	-7	-7	N/A
9/30/2021	N/A	-9	-7	-7	N/A
6/30/2021	N/A	-9	-8	-8	N/A
3/31/2021	N/A	-9	-8	-8	N/A
12/31/2020	N/A	-15	-9	-9	N/A
9/30/2020	N/A	-14	-8	-7	N/A
6/30/2020	N/A	-13	-7	-7	N/A
3/31/2020	N/A	-14	-7	-7	N/A
12/31/2019	N/A	-8	-6	-6	N/A
9/30/2019	N/A	-8	-7	-7	N/A
6/30/2019	N/A	-8	-7	-7	N/A
3/31/2019	N/A	-8	-9	-9	N/A
12/31/2018	N/A	-8	-8	-8	N/A
9/30/2018	N/A	-8	-7	-7	N/A
6/30/2018	N/A	-9	-8	-8	N/A
3/31/2018	N/A	-9	N/A	-5	N/A
12/31/2017	N/A	-10	N/A	-6	N/A
9/30/2017	N/A	-9	N/A	-7	N/A
6/30/2017	N/A	-10	N/A	-8	N/A
3/31/2017	N/A	-9	N/A	-8	N/A
12/31/2016	N/A	-11	N/A	-9	N/A
9/30/2016	N/A	-12	N/A	-7	N/A
6/30/2016	N/A	-11	N/A	-7	N/A
3/31/2016	N/A	-10	N/A	-7	N/A
12/31/2015	N/A	-5	N/A	-6	N/A
9/30/2015	N/A	-4	N/A	-6	N/A
6/30/2015	N/A	-2	N/A	-6	N/A
3/31/2015	N/A	-8	N/A	-6	N/A
12/31/2014	N/A	-7	N/A	-6	N/A
9/30/2014	N/A	-6	N/A	-7	N/A
6/30/2014	N/A	-14	N/A	-6	N/A
3/31/2014	N/A	-9	N/A	-7	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: NNVC devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: NNVC devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: NNVC devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: NNVC ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: NNVC ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de NNVC devrait être élevé dans 3 ans

NanoViricides Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 38% to US$5.25

Recent updates

NanoViricides, Inc., Annual General Meeting, Dec 07, 2024

NanoViricides, Inc. Continues Its March Towards a Phase II Clinical Trial of NV-387

NanoViricides, Inc. Provides an Update on Its Clinical Program and Strategy NV-387

NanoViricides, Inc. Announces Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virusilling, Technology Platform Intending to Revolutionize Treatment of Viral Infections

Nanoviricides, Inc. Reports Nv-387 Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

Nanoviricides, Inc. Reports Clinical Stage Lead Nanoviricide Broad-Spectrum Antiviral Drug Candidate Orally Administered Nv-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

NanoViricides, Inc. Announces A Novel Broad-Spectrum Antiviral with Activity Against RSV

NanoViricides, Inc. Announces Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

NanoViricides, Inc. Reports That the Phase I NV-387 Clinical Trial Is Completed Successfully and Data Lock Is Expected Soon

New major risk - Financial position

NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found

Insufficient new directors

NanoViricides, Inc., Annual General Meeting, Jan 13, 2024

NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2

Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development

Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2

New major risk - Revenue and earnings growth

Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides

Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well

Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

New major risk - Share price stability

Price target decreased by 38% to US$5.25

NanoViricides, Inc., Annual General Meeting, Feb 07, 2023

NanoViricides, Inc., Annual General Meeting, Dec 17, 2022

NanoViricides, Inc. announced delayed annual 10-K filing

NanoViricides, Inc. Reports Advantages Gained by Remdesivir Encapsulation

NanoViricides, Inc.(NYSEAM:NNVC) dropped from Russell Microcap Growth Index

We Think NanoViricides (NYSEMKT:NNVC) Can Afford To Drive Business Growth

New 90-day high: US$5.49

Consultant has left the company

New 90-day high: US$4.43

New 90-day low: US$3.08

Nanoviricides, Inc. Announces Board Changes

NanoViricides, Inc. announced delayed annual 10-K filing

New 90-day low: US$3.81

NanoViricides, Inc. Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19

New 90-day low - US$5.57

NanoViricides, Inc. has completed a Follow-on Equity Offering in the amount of $10 million.

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance